Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer
Study Overview
Status
Status
Conditions
Conditions
- Fallopian Tube Cancer
- Peritoneal Cavity Cancer
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Stage IV Ovarian Epithelial Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Mixed Epithelial Carcinoma
- Ovarian Undifferentiated Adenocarcinoma
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or epithelial fallopian tube carcinoma
- Patients with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, transitional cell carcinoma, and mixed epithelial carcinoma
- Patients with advanced stage refractory ovarian carcinoma: patients unable to achieve first complete remission (CR) with first or second line chemotherapy OR patients with disease relapse after achieving second CR
- Patients must be 30 days out from last chemotherapy; previous chemotherapy must include a platinumbased regimen and paclitaxel (Taxol)
- Patients must have undergone primary debulking surgery
- Patients must have a peritoneal catheter suitable for I.P. infusion
- White blood cell count (WBC) > 3.0 THOU/ul
- Serum creatinine =< 2.5 mg/dL
- ALT =< 2.5 x upper limit of normal
- AST =< 2.5 x upper limit of normal
- Total bilirubin =< 2.0 x upper limit of normal
- Albumin >= 3.0 g/dL
- Subjects must have a Performance Status Score (Zubrod/SWOG Scale) =< 2
- Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment
- Lymphocytes > 1.0 THOU/ul
- Platelets >= 100 THOU/ul
Exclusion Criteria:
- Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2
- Known history of hypersensitivity to diphtheria toxin or IL-2
- Moderate (symptomatic requiring the use of diuretics) or severe (symptomatic requiring paracentesis or other invasive intervention) ascites
- Active autoimmune disease
- Known history of pulmonary disease except controlled asthma
- Known history significant cardiac disease
- Concurrent malignancy requiring active treatment
- Clinical or radiological evidence of acute bowel obstruction within 30 days of enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Arm I
Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3.
Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Correlative studies
Other Names:
Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
Other Names:
After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and toxicity profile as assessed by the Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events version 3.0
Time Frame: From baseline
|
From baseline
|
|
MTD
Time Frame: From baseline
|
From baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy of ONTAK defined as a 25% reduction in the number of Tregs in either the peripheral blood and/or in the peritoneal cavity
Time Frame: From baseline
|
From baseline
|
|
Clinical impact on course of disease as assessed by serum CA-125 measurements
Time Frame: At baseline and at months 1, 2, 3, and 6
|
At baseline and at months 1, 2, 3, and 6
|
|
Changes in circulating cytokines IL-2, IL-6, IL-10, TGF-beta2, and TNF-alpha in the peripheral blood and at the site of disease as measured by ELISA
Time Frame: Pre- and post-treatment
|
Pre- and post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Neoplasms, Cystic, Mucinous, and Serous
- Ovarian Neoplasms
- Endometrial Neoplasms
- Carcinoma
- Adenocarcinoma
- Fallopian Tube Neoplasms
- Carcinoma, Ovarian Epithelial
- Cystadenocarcinoma, Serous
- Carcinoma, Endometrioid
- Cystadenocarcinoma
- Cystadenocarcinoma, Mucinous
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Immunologic Factors
- Interleukin-2
- Immunotoxins
- Denileukin diftitox
Other Study ID Numbers
Other Study ID Numbers
- 6193
- NCI-2010-00832
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.